ArticleDigestive diseases and sciences2025
In-Hospital Outcomes of Patients with Hepatorenal Syndrome Who Underwent Transjugular Intrahepatic Portosystemic Shunt Procedure.
Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prolonged Terlipressin Therapy as a Bridge to Curative TIPS for HRS-AKI in a Nontransplant Candidate.Case reports in hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatorenal syndrome (HRS) is a severe complication of cirrhosis associated with poor survival. The use of transjugular intrahepatic portosystemic shunt (TIPS) as a therapeutic or bridging therapy for HRS patients remains debated due to its potential severe early complications. This study aimed to retrospectively compare the in-hospital outcomes of HRS patients who received TIPS with those who did not, using a large-scale, population-based national database.
methodsThis study identified patients with HRS in National/Nationwide Inpatient Sample (NIS) database from Q4 2015-2021. A 1:3 propensity-score matching was used to match demographics, socioeconomic status, primary payer status, hospital characteristics, clinical presentations, APR-DRG mortality class, etiology of cirrhosis, and comorbidities between TIPS and non-TIPS cohorts. In-hospital outcomes were compared.
resultsThe NIS database identified 55,545 HRS patients, where 479 patients underwent TIPS. African American patients and those in rural or smaller hospitals were significantly less likely to receive TIPS. Following propensity-score matching, 1,441 HRS patients who did not undergo TIPS were matched to all patients who underwent the procedure. In-hospital mortality (22.59% vs 24.36%, p = 0.46), hepatic encephalopathy (37.87% vs 35.95%, p = 0.48), and liver transplantation rates (7.11% vs 8.26%, p = 0.50) were comparable between patients who underwent TIPS and those who did not. However, patients who underwent TIPS had a longer length of stay (p < 0.01) and higher total hospital charges (p < 0.01) but had a lower transfer-out rate (p < 0.01).
conclusionTIPS does not appear to negatively impact immediate outcomes and could be considered as a potentially therapeutic treatment option for suitable candidates, considering its long-term benefits. Future studies should focus on the long-term prognosis of patients who received TIPS and the potential role of TIPS as a bridging therapy to liver transplantation. Moreover, there could be potential racial and institutional disparities in accessing/offering TIPS that may warrant further investigation.
Indexed as
Identifiers
40495002What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.